Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer

BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, is a limited factor in the treatment of non-small-cell lung cancer (NSCLC) patients. Therefore, ongoing studies are trying to identify EGFR-TKIs-resistant mechanisms and to discover...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Inae, Song, Jayoung, Bae, Song Yi, Lee, Sang Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Cancer Prevention 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951316/
https://www.ncbi.nlm.nih.gov/pubmed/31950021
http://dx.doi.org/10.15430/JCP.2019.24.4.217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951316/
https://www.ncbi.nlm.nih.gov/pubmed/31950021
http://dx.doi.org/10.15430/JCP.2019.24.4.217

Ejemplares similares